Surgical Techniques in Neurosurgery
Modern neurosurgical techniques combine microsurgical precision, intraoperative imaging, and advanced navigation to maximise safety and effectiveness. Each procedure is tailored to the individual patient's anatomy, pathology, and functional requirements.
Craniotomy — Surgical Principles & Techniques
A craniotomy involves temporary removal of a bone flap to access the brain. The flap is replaced at the end of the procedure. It is the fundamental cranial surgical technique adapted for almost every intracranial pathology.
- Patient positioning — Supine (frontal, parietal, temporal), prone (posterior fossa, occipital), lateral (temporal, subtemporal approaches). Head fixed in Mayfield clamp
- Scalp incision — Planned to maximise surgical exposure while preserving scalp vascularity and avoiding motor/sensory cortex. Temporalis muscle preserved where possible
- Bone flap — Multiple burr holes connected with craniotome (power drill). At BVH: manual Hudson brace + Gigli saw during craniotome restoration period. Target: <60 min total craniotomy time
- Dural opening — Cruciate or curvilinear incision; tack-up sutures prevent epidural haematoma. Microsurgical work through dural window under Zeiss microscope
- Intraoperative CT (BodyTom) — Portable full-body CT scanner wheeled into OT; confirms extent of resection or position of instruments mid-procedure. Unique capability at BVH
- Haemostasis — Bipolar cautery, haemostatic agents (Surgicel, Gelfoam), bone wax for diploic bleeding
- Closure — Watertight dural closure (primary or pericranial patch). Bone flap reattached with titanium plates. Scalp wound closure in layers
Common Craniotomy Approaches
| Approach | Target | Position |
|---|---|---|
| Pterional (frontotemporal) | ACoA, MCA aneurysms; anterior skull base; pituitary (transcranial) | Supine, head rotated 30–45° |
| Frontal/bifrontal | Olfactory groove meningioma; frontal glioma; bifrontal contusion | Supine, neck flexed |
| Parieto-occipital | Posterior convexity tumours; parasagittal meningioma; PCA AVM | Supine or lateral |
| Retrosigmoid | Acoustic neuroma; posterior fossa tumour; cerebellopontine angle | Semi-sitting, park bench, or lateral |
| Suboccipital (midline) | 4th ventricle tumours; Chiari decompression; posterior fossa haematoma | Prone or sitting |
| Temporal | Temporal lobe tumours; MCA aneurysm; TLAS epilepsy surgery | Supine, head lateral |
Awake craniotomy allows real-time monitoring of neurological function during tumour resection near eloquent cortex — maximising safe tumour removal while preventing permanent neurological deficits.
- AAA protocol (Asleep-Awake-Asleep) — General anaesthesia for opening, patient awakened during resection, re-anaesthetised for closure. Propofol/dexmedetomidine target-controlled infusion
- Scalp block — Regional anaesthesia with bupivacaine; renders the skull opening pain-free while awake
- Cortical mapping — Direct electrical stimulation of cortical surface identifies motor, speech, and sensory areas; surgeon avoids positive-response areas during resection
- Patient tasks — Speaking (counting, naming objects), moving hand, following commands. Any change = surgeon stops at that margin
- BVH Practice — Awake craniotomy performed without formal IONM; clinical monitoring by dedicated anaesthesiologist + neurologist + surgeon team. Patients selected for cooperative temperament, good reserve, and accessible tumour location
- Outcomes — Increases extent of resection by ~20%; reduces permanent neurological deficits from 10% → 3% for eloquent area tumours
Stereotactic biopsy uses a 3D coordinate system to precisely target deep, small, or eloquent-area brain lesions for tissue diagnosis without open craniotomy.
- Frame-based (ARC + BodyTom at BVH) — Inomed ARC stereotactic frame fixed to skull; BodyTom CT acquired with fiducial markers; 3D coordinates calculated; 14G biopsy needle directed to target. Diagnostic yield: 90–95%
- Indications — Deep glioma (thalamus, basal ganglia); brainstem lesion; lymphoma (avoid resection, needs tissue); small enhancing lesion of unknown type; lesion in eloquent cortex
- Haemorrhage risk — 1–2% symptomatic; higher for vascular lesions. Pre-op MRA to exclude vascular target. Stop aspirin 7 days prior
- Rapid intraoperative pathology — Frozen section during biopsy confirms adequate tissue before frame removal
Removal of a large bone flap (NOT replaced) to allow brain expansion and relieve refractory raised ICP. Life-saving in malignant cerebral oedema.
- Malignant MCA infarction — ≥10cm frontoparieto-temporal craniectomy within 48h; DESTINY/HAMLET trials: mortality reduced 78% → 29%
- TBI — DECRA trial: bifrontal craniectomy for refractory ICP; RESCUEicp trial showed reduced mortality but increased severe disability; patient selection critical
- Duraplasty mandatory — Expansion dura with pericranial graft to fully accommodate swelling
- Cranioplasty — Bone flap stored (frozen or autoclaved) or titanium/PMMA custom implant placed at 8–12 weeks post-op once swelling resolved
Spine Surgery — Decompression, Fusion & Instrumentation
Educational video · تعلیمی ویڈیو
Watch on YouTube · یوٹیوب پر دیکھیںCase Presentation: Robotic Spinal Decompression and Fusion Surgery
Johns Hopkins Medicine · YouTube
- Posterior midline approach; tubular retractor or microscope-assisted 2cm incision
- Ipsilateral hemilaminotomy; dural retraction; herniated fragment removal
- Day 1–2 post-op mobilisation; 85–90% excellent/good outcomes at 1 year
- Hospital stay 1–2 days; driving restriction 2–4 weeks; heavy work 6–8 weeks
- At BVH: performed under Zeiss microscope with Moon Ray C-arm level confirmation
- Posterior approach; pedicle screw placement (4 screws minimum for single level); intervertebral PEEK cage + bone graft
- Fluoroscopy-guided pedicle screw insertion (Moon Ray C-arm at BVH); BodyTom CT post-instrumentation for verification
- Fusion rate: 90–95% at 12 months with autograft iliac crest bone or OP-1
- Hospital stay 4–7 days; lumbar brace 6–12 weeks; return to light work 6–8 weeks; heavy work 3–6 months
- Right-sided neck incision (left side for >C5 to avoid non-recurrent laryngeal nerve risk)
- Discectomy + PEEK cage or bone graft + anterior plate fixation (Synthes, DePuy systems)
- Intraoperative somatosensory EP monitoring recommended for myelopathy (where available)
- Patient discharged day 2–3; soft collar 4 weeks; bone fusion assessed at 3 months (CT scan)
- Adjacent segment disease (ASD) risk: ~3%/year; total disc replacement (TDR) reduces ASD risk
- Bilateral laminae removed exposing dura and nerve roots; ligamentum flavum excised
- Lumbar laminectomy: 85% satisfaction for neurogenic claudication at 5 years (SPORT 2008)
- Cervical laminoplasty (preferred over cervical laminectomy): opens canal while preserving posterior tension band; reduces post-laminectomy kyphosis
- Combined with lateral mass screws/rods if instability present (laminectomy + fusion)
Endoscopic Neurosurgery
Educational video · تعلیمی ویڈیو
Watch on YouTube · یوٹیوب پر دیکھیںEndoscopic Transsphenoidal Pituitary Surgery Explained
Barrow Neurological Institute · YouTube
Stereotactic Radiosurgery (SRS)
SRS delivers a single high dose of precisely focused radiation to an intracranial target using multiple convergent beams. The surrounding brain receives a fraction of the dose. It is not conventional surgery — no incision — but achieves surgical-equivalent outcomes for selected conditions. Available at Shaukat Khanum Cancer Hospital (Lahore), AKUH (Karachi), and selected PNS hospitals.
| Indication | System | Dose | Outcomes | Evidence |
|---|---|---|---|---|
| Brain Metastases (<3cm, ≤4 lesions) | Gamma Knife / Cyberknife | 15–24 Gy single fraction | 90% local control at 1 year; avoids WBRT cognitive side effects | Level I |
| Acoustic Neuroma (<3cm) | Gamma Knife preferred | 12–13 Gy margin dose | 95% growth control; 70–80% hearing preservation | Level I |
| Meningioma (Grade I, residual) | Gamma Knife / Linear accelerator | 12–15 Gy | 95–97% control at 5 years; cavernous sinus ideal | Level I |
| AVM (<3cm, Spetzler-Martin I–III) | Gamma Knife | 20–25 Gy margin dose | 80% obliteration at 2–3 years; haemorrhage risk persists until obliteration | Level II |
| Trigeminal Neuralgia | Gamma Knife (retrogasserian) | 80–90 Gy | 75–85% pain relief; 10–15% numbness | Level II |
| Pituitary Adenoma (residual) | Gamma Knife | 12–18 Gy (margin) | Hormonal control 40–70%; hypopituitarism risk 20–30% | Level II |
Dr. Wasif coordinates radiosurgery referrals to Shaukat Khanum Cancer Hospital Lahore (Gamma Knife / TrueBeam), AKUH Karachi (Cyberknife), and NORI Islamabad. Planning MRI and case summary provided at time of referral.
Medical Management of Neurosurgical Conditions
Core Drug Classes — Neurosurgical Practice
| Drug Class | Drug / Brand (Pakistan) | Indication | Key Dose | Notes |
|---|---|---|---|---|
| Corticosteroid | Dexamethasone | Cerebral oedema (tumour/abscess). NOT for TBI (CRASH trial) | 4–10mg IV/PO QID; taper over 2–4 weeks | Raises blood glucose; PPI cover; mood change; myopathy if prolonged |
| Osmotherapy | Mannitol 20% | Acute raised ICP; cerebral herniation | 0.5–1g/kg IV bolus q4–6h; Serum Osm <320 | Rebound ICP if prolonged; monitor renal function; serum osmolality |
| Osmotherapy | 3% Hypertonic Saline | Refractory ICP; preferred if hypovolaemia | 2–3ml/kg bolus; Na target 150–160 mEq/L | Better volume expansion than mannitol; central line preferred |
| Antiepileptic — 1st line | Levetiracetam (Levelanz) | Peri-operative seizure prophylaxis; post-TBI 7 days; focal epilepsy | 500–1000mg BD | No monitoring; no CYP450 interactions; mood side effects in ~10% |
| Antiepileptic — focal | Lacosamide (Lalap) | Focal-onset seizures; adjunct or monotherapy | 50mg BD → 100–200mg BD | Sodium channel slow inactivation; IV loading 200mg available |
| Neuropathic pain | Mirogabalin (MIRONEU) | Radiculopathy; post-herpetic neuralgia; peripheral neuropathy | 5mg BD → 10–15mg BD (titrate 2 weekly) | Renal adjustment CrCl <30; superior α2δ selectivity vs pregabalin |
| Anticoagulation — LMWH | Enoxaparin (Clexane, Hoechst PK) | DVT prophylaxis post-neuro-surgery; CVST acute treatment; VTE | Prophylaxis: 40mg OD. Therapeutic: 1mg/kg BD | Check anti-Xa for renal impairment; avoid if platelet <50,000 |
| Anticoagulation — oral | Warfarin | CVST maintenance; cardioembolic stroke; VTE long-term | INR 2.0–3.0 | Safe in breastfeeding (CVST postpartum); regular INR monitoring |
| Antiplatelet | Aspirin (Loprin/Ascard) + Clopidogrel (Plavix Plus) | Ischaemic stroke/TIA secondary prevention | Aspirin 75mg OD + Clopidogrel 75mg OD × 21 days → monotherapy | POINT trial: dual antiplatelet × 21 days for minor stroke/TIA |
| Vasospasm prevention | Nimodipine (Nimotop) | Post-SAH vasospasm prevention | 60mg PO q4h × 21 days | Level I evidence; do NOT use IV (hypotension risk); start immediately on SAH diagnosis |
| Analgesic — NSAID+PPI combo | LOVANZO-D (Diclofenac 75mg + Dexlansoprazole 20mg) | Post-operative pain; radiculopathy; post-surgical inflammation | 1 tablet OD with meal | Gastroprotection built-in; avoid post-craniotomy (renal risk); max 2 weeks post-op |
| Muscle relaxant | Baclofen | Post-SCI spasticity; cervical myelopathy spasticity | 5–20mg TID; titrate slowly | Abrupt withdrawal = seizures and hyperthermia. Never stop suddenly |
| Calcium channel blocker | Amlodipine / Nifedipine | Blood pressure control post-craniotomy; SAH-associated hypertension | 5–10mg OD | Avoid sublingual nifedipine (precipitous BP drop — increases ischaemia) |
| Supplement | Magnesium Glycinate (AXIUM, Genetics Pharma) | Muscle cramps; nerve irritability; migraine prophylaxis | 300–400mg elemental Mg OD | Glycinate form: superior GI tolerability. Check serum Mg before aggressive supplementation |
Epilepsy Surgery
Educational video · تعلیمی ویڈیو
Watch on YouTube · یوٹیوب پر دیکھیںTypes of Epilepsy Surgery – Mayo Clinic
Mayo Clinic · YouTube
Surgical resection of the epileptogenic focus offers 60–80% seizure freedom for properly selected drug-resistant epilepsy patients. Pre-surgical evaluation requires high-resolution MRI (3T preferred), video-EEG monitoring, neuropsychological testing, and functional mapping of eloquent cortex.
Trigeminal Neuralgia — Treatment Ladder
Educational video · تعلیمی ویڈیو
Watch on YouTube · یوٹیوب پر دیکھیںTrigeminal Neuralgia Pain Relieving Surgery
Atrium Health · YouTube
Trigeminal neuralgia (TN) causes paroxysmal lancinating facial pain in V2/V3 distribution, triggered by light touch (eating, talking, brushing teeth). Most common cause: vascular compression of CN V at root entry zone. Treatment proceeds stepwise from medical to surgical.
200–1200mg/day; 70–80% initial response. Monitor CBC (aplastic anaemia rare), LFTs, sodium (hyponatraemia). Oxcarbazepine 300–1800mg/day: better tolerated, fewer drug interactions (second-line).
Baclofen 10–80mg/day; lamotrigine 25–400mg/day; gabapentin 300–3600mg/day as adjuncts. Amitriptyline 10–75mg OD for atypical TN (burning component). Duloxetine for mixed neuropathic-type TN.
Glycerol injection, balloon compression, or radiofrequency thermorhizotomy of Gasserian ganglion. 80–90% immediate pain relief; higher recurrence than MVD (30–40% at 5 years). Ideal for elderly/medically unfit patients.
80–90 Gy to retrogasserian segment of CN V. 75–85% pain relief at 6 months; peak effect at 1–2 months. Risk of numbness 10–15%. Recurrence 20% at 5 years. Non-invasive; ideal for high surgical risk.
Retrosigmoid craniotomy; Teflon felt placed between offending vessel and CN V root. 90% immediate pain relief; 80% free at 5 years; 70% at 10 years. Best long-term results. Available at neurosurgical centres. Suitable for fit patients without MS.
Deep Brain Stimulation (DBS)
DBS delivers chronic high-frequency electrical stimulation to specific deep brain targets via implanted electrodes and an implantable pulse generator (IPG). It modulates dysfunctional neural circuits without destroying tissue — reversible and adjustable. Framework available at BVH (electrodes); IPGs procured individually.
| Indication | Target | Expected Outcome | Evidence |
|---|---|---|---|
| Parkinson's Disease | Subthalamic nucleus (STN) or Globus pallidus internus (GPi) | 40–60% improvement in motor UPDRS; reduction in levodopa dose 30–50%; improved "on" time | Level I |
| Essential Tremor | Ventral intermediate nucleus (VIM) of thalamus | 70–90% tremor reduction; durable. HIFU (focused ultrasound) emerging as non-invasive alternative | Level I |
| Dystonia (Primary) | Globus pallidus internus (GPi) | 50–70% improvement in DYS-RATING; slower response than PD (months) | Level II |
| OCD (Refractory) | Anterior limb internal capsule / nucleus accumbens | 35–50% improvement in Y-BOCS; FDA humanitarian device exemption | Level III |
| Treatment-Resistant Depression | Subgenual cingulate cortex (Cg25) | 50–60% response in carefully selected patients; investigational | Investigational |
Neurorehabilitation
Neurorehabilitation is an essential component of neurosurgical care — often determining functional outcome more than the surgery itself. A dedicated multidisciplinary team approach is fundamental, starting from the ICU and continuing in the community.
Evidence-Based Alternative & Complementary Approaches
Always inform your neurosurgeon about any supplements or alternative treatments. Some interact with medications (e.g., St John's Wort reduces dexamethasone, warfarin, and AED levels by up to 50% via CYP3A4 induction). Alternative medicine complements — it does not replace — evidence-based neurosurgical care.
Level A evidence for post-operative pain reduction and chemotherapy-induced nausea. Moderate evidence for chronic low back pain and radiculopathy. Cochrane 2018 meta-analysis: 50% pain reduction vs sham acupuncture for chronic low back pain.
Reduces anxiety, depression, and pain catastrophising in brain tumour and chronic pain patients. 8-week MBSR programme reduces pain disability by 30% (JAMA Internal Medicine 2016). Recommended alongside conventional treatment.
Cochrane review: yoga superior to no-exercise for chronic low back pain (Level B). Tai Chi reduces fall risk in elderly neurological patients by 40%. Iyengar yoga recommended for cervical and lumbar disorders.
Anti-inflammatory via NF-κB pathway; pre-clinical anti-glioma activity. 500mg TID with piperine (black pepper) for bioavailability (20-fold increase). Safe alongside standard treatment at recommended doses. Avoid with warfarin (antiplatelet effect).
Reduces systemic inflammation; neuroprotective potential. 2–4g EPA+DHA daily. May reduce post-operative cognitive dysfunction. Meta-analysis shows 15–20% reduction in depression co-morbidity with neurological illness.
Licensed for Dravet syndrome and Lennox-Gastaut (Epidyolex — FDA/EMA approved). Pre-clinical synergy with temozolomide in GBM. Non-psychoactive CBD oil (≤0.2% THC): may reduce chemotherapy nausea and improve sleep. Legal status varies in Pakistan.
Deficiency highly prevalent in Pakistan; linked to chronic musculoskeletal pain, cognitive decline, and MS risk. Target 25-OH VitD >75 nmol/L. Cholecalciferol 2000–4000 IU/day for deficiency correction. Safe, inexpensive, widely available.
The spiritual dimension is central to recovery in our patient community. Islamic practices — Ruqyah, Dua, Quran recitation — provide psychological support, hope, and acceptance (tawakkul على الله). Studies show strong spiritual beliefs improve pain tolerance and quality of life (Puchalski et al, J Palliat Med). We actively support and encourage spiritual care alongside conventional treatment.
St John's Wort: CYP3A4 inducer → reduces dexamethasone, warfarin, AED, immunosuppressant levels by 30–60%. AVOID completely with any neurosurgical medications. Ginkgo biloba: antiplatelet — stop 7 days before surgery. Garlic/ginger high-dose: antiplatelet — stop 7 days pre-op.
Neurosurgery is a science grounded in anatomy and evidence — but healing is a human experience encompassing body, mind, and spirit. We welcome complementary approaches that support the patient's wellbeing alongside their surgical treatment, provided they are disclosed, safe, and do not interfere with conventional care. Our approach is informed by tawakkul — complete reliance on Allah — combined with the best available medical evidence.